Dr. Shilpa Gupta - Haemato Oncology | Bombay Hospital

Dr. Shilpa Gupta

MBBS, MD (Med), Fellowship Hemato-oncology

Book Appointment

Dr. Shilpa Gupta - Haemato-Oncologist Profile and Consultation Details
Speciality	Haemato-Oncologist
Qualifications	MBBS, MD (Med), Fellowship Hemato-oncology
Extn. No.	293
Area Of Interest	Blood Cancers; CAR-T cell therapy
Research & Publications	• Accepted on 24/03/2026 for publication in Mediterranean Journal of Hematology and Infectious diseases. Gupta et al. Simultaneous presentation of Hemophagocytic Lymphohistiocytosis and Classical Hodgkin's Lymphoma in a patient with underlying germline homozygous STXBP2 Mutation. • Primary extranodal classical Hodgkin lymphoma presenting as a chest wall mass mimicking tuberculosis: A rare case report with long-term follow-up (P. Jujjuvarapu, S. Gupta, & V. . Dalal, Trans.). (2026). Indian Journal of Case Reports, 11(12), 634-637. • Gupta S. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series. Leukemia & Lymphoma, 2012. Book Chapter: Gastrointestinal Lymphomas in Recent Advances in Surgery - 2012, Jaypee Publications. Peer-review journal reviewer Principal Investigator / Co-Investigator in multiple trials, including: • 2024 \| Phase III \| Observational study on anticoagulant prescribing patterns - Principal Investigator. 2023 \| Phase III \| PZN-128 in Chronic ITP - Principal Investigator. Earlier experience: Multiple Phase III trials in colorectal cancer, breast cancer, T-cell lymphoma, ovarian cancer, and pancreatic cancer (2015-2017). • PI: Phase II/III trial of masitinib with dexamethasone and gemcitabine in relapsed/refractory peripheral T-cell lymphoma. (National, Completed 2016) • Co-I: BA-BE study of Mylan's Doxorubicin Hydrochloride Liposome vs. Sun Pharma's reference in ovarian cancer patients after platinum chemotherapy. (National, Completed 2017) • Co-I: Phase III study of Selinexor, Bortezomib, and Dexamethasone (SVd) in relapsed/refractory multiple myeloma. (International, Completed 2018) • Co-I: BA-BE study comparing Zydus Rituximab vs. Roche/Genentech reference in DLBCL. (National, Completed 2018) • Co-I: BA-BE study comparing Cadila Trastuzumab Emtansine vs. Kadcyla (Roche) in HER2-positive metastatic breast cancer. (National, Completed 2018) • PI: Phase III international study of PZN-128 subcutaneous injection vs. comparator in chronic immune thrombocytopenic purpura. (Completed 2023) • PI: Observational study on anticoagulant prescription factors and outcomes. (Investigator-initiated, Completed 2024)
Experience (in yrs)	16
Awards/Achievements	• Awarded “Promising Oncologist Award” at Times group at Times Oncology Conclave, 3rd Prize – Poster Presentation, European School of Oncology / ICML, 2012. • Awarded JRD Tata Scholarship and Ratan Tata (M.B.B.S.) \| Distinction in Microbiology & Biochemistry. • Ranked 142nd in PGM-CET 2006; 33rd in MH- CET 2000.
Contact Details	Email : shilpagupta0707@gmail.com, Contact No. : 9324319248 / 9820803843
Consulting Days & Timings	Monday to Saturday: 2pm - 4pm
Consulting Room	128